Nathalie Neirynck

Nathalie Neirynck

Auto-generated profile, based on publicly available information

Nathalie Neirynck

Nephrology Section, Department of Internal Medicine, Ghent University Hospital, Ghent, Belgium

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2015 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NNNathalie Neirynck
Nathalie Neirynck
GGGriet Glorieux
Griet Glorieux
ESEva Schepers
Eva Schepers
FVFrancis Verbeke
Francis Verbeke
RVRaymond Vanholder
Raymond Vanholder
Soluble tumor necrosis factor receptors 1 (sTNFR1) and 2 (sTNFR2) have been associated to progression of renal failure, end stage renal disease and mortality in early stages of chronic kidney disease (CKD), mostly in the context of diabetic nephropathy. The predictive value of these markers in advanced stages of CKD irrespective of the specific causes of kidney disease has not yet been defined. In this study, the relationship between sTNFR1 and sTNFR2 and the risk for adverse cardiovascular events (CVE) and all-cause mortality was investigated in a population with CKD stage 4-5, not yet on dialysis, to minimize the confounding by renal function. In 131 patients, CKD stage 4-5, sTNFR1, sTNFR2 were analysed for their association to a composite endpoint of all-cause mortality or first non-fatal CVE by univariate and multivariate Cox proportional hazards models. In the multivariate models, age, gender, CRP, eGFR and significant comorbidities were included as covariates. During a median follow-up of 33 months, 40 events (30.5%) occurred of which 29 deaths (22.1%) and 11 (8.4%) first non-fatal CVE. In univariate analysis, the hazard ratios (HR) of sTNFR1 and sTNFR2 for negative outcome were 1.49 (95% confidence interval (CI): 1.28-1.75) and 1.13 (95% CI: 1.06-1.20) respectively. After adjustment for clinical covariables (age, CRP, diabetes and a history of cardiovascular disease) both sTNFRs remained independently associated to outcomes (HR: sTNFR1: 1.51, 95% CI: 1.30-1.77; sTNFR2: 1.13, 95% CI: 1.06-1.20). A subanalysis of the non-diabetic patients in the study population confirmed these findings, especially for sTNFR1. sTNFR1 and sTNFR2 are independently associated to all-cause mortality or an increased risk for cardiovascular events in advanced CKD irrespective of the cause of kidney disease.

31 August 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
NNNathalie Neirynck
Nathalie Neirynck
SESunny Eloot
Sunny Eloot
GGGriet Glorieux
Griet Glorieux
DBDaniela V. Barreto
Daniela V. Barreto
FBFellype C. Barreto
Fellype C. Barreto
RVRaymond Vanholder
Raymond Vanholder
Uremic solute concentration increases as Glomerular Filtration Rate (GFR) declines. Weak associations were demonstrated between estimated GFR (eGFR) and the concentrations of several small water-soluble and protein-bound uremic solutes (MW500Da). In 95 CKD-patients (CKD-stage 2–5 not on dialysis), associations between different eGFR-formulae (creatinine, CystatinC-based or both) and the natural logarithm of the concentration of several LMWP’s were analyzed: i.e. parathyroid hormone (PTH), Cystatin C (CystC), interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), leptin, retinol binding protein (RbP), immunoglobin light chains kappa and lambda (Ig-κ and Ig-λ), beta-2-microglobulin (β2M), myoglobin and fibroblast growth factor-23 (FGF-23)). The regression coefficients (R2) between eGFR, based on the CKD-EPI-Crea-CystC-formula as reference, and the examined LMWP’s could be divided into three groups. Most of the LMWP’s associated weakly (R2 0.7). Almost identical R2-values were found per LMWP for all eGFR-formulae, with exception of CystC and β2M which showed weaker associations with creatinine-based than with CystC-based eGFR. The association between eGFR and the concentration of several LMWP’s is inconsistent, with in general low R2-values. Thus, the use of eGFR to evaluate kidney function does not reflect the concentration of several LMWP’s with proven toxic impact in CKD.

20 January 2015 in Nephrology Dialysis Transplantation
Verified
Journal Article
Open access
PDF file
NNNathalie Neirynck
Nathalie Neirynck
GGGriet Glorieux
Griet Glorieux
ESEva Schepers
Eva Schepers
ADAnnemieke Dhondt
Annemieke Dhondt
FVFrancis Verbeke
Francis Verbeke
RVRaymond Vanholder
Raymond Vanholder
Pro-inflammatory cytokines are elevated in chronic kidney disease (CKD), a condition characterized by microinflammation with oxidative stress as key feature. However, their role in the inflammatory response at uraemic concentrations has not yet been defined. In this study, the contribution of cytokines on induction of leukocyte oxidative stress was investigated. Whole blood from healthy donors was incubated with 20–1400 pg/mL TNFα, 5–102.8 pg/mL IL-6, 20–400 pg/mL IL-1β and 75–1200 pg/mL IL-18 separately or in combination. Oxidative burst was measured, at baseline and after stimulation with fMLP (Phagoburst™). The effect of the TNFα blocker, adalimumab (Ada), was evaluated on TNFα-induced ROS production. Finally, the association between TNFα and the composite end point all-cause mortality or first cardiovascular event was analysed in a CKD population stage 4–5 (n = 121). While interleukin (IL)-6, IL-1β and IL-18 alone induced no ROS activation of normal leukocytes, irrespective of concentrations, TNFα induced ROS activation at baseline (P < 0.01) and after fMLP stimulation (P < 0.05), but only at uraemic concentrations in the high range (400 and 1400 pg/mL). A similar pattern was observed with all cytokines in combination, but already at intermediate uraemic concentrations (all P < 0.05, except for monocytes after fMLP stimulation: n.s.), suggesting synergism between cytokines. ROS production induced by TNFα (400 pg/mL) and the cytokine combination was blocked with Ada. Uraemia-related oxidative stress in leukocytes of haemodialysis patients was however not blocked by Ada. In patients, TNFα was not associated to adverse events (HR: 1.52, 95% CI 0.81–2.85, P = 0.13). Among several pro-inflammatory cytokines, TNFα alone was pro-oxidative but only at high-range uraemic concentrations. Adding a TNFα blocker, Ada, blocked this ROS production, but not the oxidative stress in blood samples from haemodialysis patients, suggesting that other uraemic toxins than TNFα are more crucial in this process. However, the lack of association between TNFα and mortality suggests that the role of TNFα-linked oxidative stress is limited.

1 November 2013 in Journal of Renal Nutrition
Verified
Journal Article
Closed access
PDF file
NNNathalie Neirynck
Nathalie Neirynck
GGGriet Glorieux
Griet Glorieux
JBJente Boelaert
Jente Boelaert
ESEva Schepers
Eva Schepers
SLSophie Liabeuf
Sophie Liabeuf
RVRaymond Vanholder
Raymond Vanholder

1 October 2015
Verified
Book Chapter
Closed access
Griet GlorieuxGriet Glorieux
Griet Glorieux
NNNathalie Neirynck
Nathalie Neirynck
APAnneleen Pletinck
Anneleen Pletinck
ESEva Schepers
Eva Schepers
RVRaymond Vanholder
Raymond Vanholder

24 May 2018
Verified
Book
Closed access
Griet GlorieuxGriet Glorieux
Griet Glorieux
NNNathalie Neirynck
Nathalie Neirynck
APAnneleen Pletinck
Anneleen Pletinck
ESEva Schepers
Eva Schepers
RVRaymond Vanholder
Raymond Vanholder
The uraemic syndrome is a complex mixture of organ dysfunctions attributed to the retention of a multitude of compounds that under normal conditions are excreted by healthy kidneys. Although important progress has been made in the identification and characterization of uraemic retention solutes and in the revealing of their pathophysiological effects, this knowledge remains far from complete. Data are discussed on general characteristics of specific uraemic retention solutes, on in vitro and in vivo biological effects and on available observational and interventional studies with respect to their removal and related patient outcome are discussed.